Back to search

Aristotle University Of Thessaloniki (AUTH)

Μοριακή μελέτη του υπεύθυνου για την αγγειογένεση αυξητικού παράγοντα του αγγειακού ενδοθήλιου (VEGF) σε ασθενείς με οξεία μυελογενή λευχαιμία

Abstract

dc:description

Angiogenesis is a complex and multistage process that leads to the generation of new blood vessels from preexisting blood vessels. Recent research as well as clinical studies showed that angiogenesis is essential for tumour growth, penetration and metastasis. The role of angiogenesis has been described in almost all human solid tumour, in some of them seems to relate with the prognosis and the process of the disease, and also with the survival of the patients. However, the mechanism that controls angiogenesis has not been elucidated until now. Nowadays, the idea of the “angiogenic switch” is generally accepted, meaning that the fuse of angiogenesis is caused by the disturbance of the dynamic balance between the inducers and the inhibitors of angiogenesis, even though the mechanism that controls this process in a tumour is yet to be clarified. The most significant inducer of angiogenesis is the Vascular Endothelial Growth Factor (VEGF), which forms the initial moderator of the physiological and the pathologic angiogenesis. For years now, angiogenesis has been a matter of research mainly for the study of solid tumours. Research for the correlation of angiogenesis and hematologic malignancies is more recent and even though there is clear evidence for a relationship between angiogenesis and some of them, its relationship with Acute Myeloid Leukaemia (AML) is not yet clarified. The first report for the existence of possible correlation between angiogenesis and AML dates back to 1997. From then on several studies took place with the aim to further evaluate the above correlation. However, studies led to contradictory results and consequently the exact role of angiogenesis in AML remains ambiguous. The purpose of this particular research is the study of angiogenesis on patients with AML in order to clarify whether and to what extend it participates in pathogenesis and prognosis of the disease and in the response of patients in the treatment. As well as to clarify the possible correlation between VEGF expression and hematologic findings and prognostic factors. The discrepancy of the results in many papers according to angiogenesis in AML underlined the main motive for this research. We consider that it would be helpful the measurement of VEGF mRNA in all cell types that resident in the bone marrow with the use of Real Time RT-PCR (Real Time Reverse Transcriptase-PCR) method. This method, which applied for first time in the current research for the study of AML patients, is fast, has the advantage of accuracy and repeatability and also provides the quantification of VEGF, even small number of transcripts. Therefore, the results that connote are more credible and appreciable. Forty (40) AML patients were studied at diagnosis and 18 of them in complete hematologic remission after chemotherapy, while 22 healthy individuals used as controls. A) The expression of VEGF was determined in protein level with the use of immunoenzymatic assay ELISA in patient’s serum and in mRNA level in the bone marrow of AML patients with the use of Real Time RT-PCR method. Β) The microvessel density was evaluated by counting the CD34 stained vessels in biopsies of AML patients at diagnosis. The VEGF protein concentration in control group was 69,48 ± 136,04 pg/ml, in AML patients at diagnosis 212,27 ± 214,29 pg/ml and in AML patients in remission 570,18 ± 569,39 pg/ml. In control group and in all patients were found a significant positive correlation between the VEGF concentration and the platelets count, while there was no correlation with other hematologic parameter. Additionally, there seems to be a statistically significant increase in protein concentration in patients with de novo AML compared to patients with secondary AML, and in patients with unfavorable FAB subtype compared to patients with favorable FAB subtype. The mRNA levels of VEGF obtained from patients during diagnosis were statistically significant reduced compared to control group by 4.218 times (p=0.038). For patients that were in remission those levels were similar to those of the normal individuals. Moreover, statistically significant difference was found between patients at diagnosis and patients in remission. More specifically, patients at diagnosis had 3.704 times (p=0.001) lower levels compared to patients in remission. There was found a negative correlation between mRNA levels of VEGF and the percentage of the blasts, while there was no correlation to other hematologic parameters. Nonetheless, there seem to be statistically significant higher levels at patients with de novo ΑML and unfavourable FAB subtype compared to those with secondary AML and unfavourable FAB subtype. What is also worth noting is that a positive correlation between the levels of mRNA and the concentration of the VEGF protein was found in patients at diagnosis and in remission, whilst this correlation was not confirmed for the control group. This finding is probably due to the increased requirement of leukemic cells for survival and proliferation, a fact that could achieved via the translation of mRNA to protein. On the contrary, in control group the absence of correlation it could be explained by the fact that mRNA was composed but remained as a “pool” in the cell waiting the appropriate stimulus from the environment in order to translate to protein. Finally, for the direct evaluation of angiogenesis we determined the microvessel density using the anti-CD34 antigen in 22 AML patients at diagnosis and in 10 individuals with normal bone marrow that were used as controls. In patients at diagnosis the microvessel density were 5,78 ± 3,15 vessels per optical field, while in the control group were 1,61 ± 0,56 vessels per optical field (p=0,013). There was found no correlation between the number of the vessels and the hematologic parameters, the prognostic factors and the VEGF protein concentration or mRNA levels. In conclusion, increased angiogenesis was observed at the diagnosis of AML, as it emerged through the increased microvessel density and the increased levels of VEGF protein in the serum of the patients. The angiogenic factor VEGF was signified in the AML patients at diagnosis both in mRNA level as well as in protein level and it increased even more at patients in remission. It could well be that the increase in the VEGF levels was caused by the fermentations taking place in the microenvironment of the bone marrow with the aim to regenerate itself after chemotherapy, as well as by possible secretion of the factor apart from the leukemic cells and the normal cells, like stromal cells or hematopoietic stem cells of the bone marrow. The molecular mechanism with which VEGF is produced seems to be heterogeneous in AML as well as dependant not only on the release of cytokines and growth factors, but also on its production by several cell types, leukemic or not. According to our results we conclude that neither microvessel density nor VEGF can constitute prognostic factors in AML patients. Furthermore, antiangiogenic therapy, especially this that targets VEGF or its receptors, cannot be confirmed either by our study or others that can be used as a new therapeutic approach in AML.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2008

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Αυγητίδου, Αγγελική
  • Avgitidou, Aggeliki

Subjects

dc:subject × 11

Rights

Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/19486

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Αυγητίδου, Αγγελική; Avgitidou, Aggeliki. Μοριακή μελέτη του υπεύθυνου για την αγγειογένεση αυξητικού παράγοντα του αγγειακού ενδοθήλιου (VEGF) σε ασθενείς με οξεία μυελογενή λευχαιμία. Aristotle University Of Thessaloniki (AUTH), 2008. http://hdl.handle.net/10442/hedi/19486